Patient Leaflet Updated 10-Sep-2024 | Dr. Reddy's Laboratories (UK) Ltd
Atazanavir 200 mg, 300 mg Capsules, Hard
Atazanavir 200 mg, 300 mg Capsules, Hard
Atazanavir
1. What Atazanavir is and what it is used for
2. What you need to know before you take Atazanavir
3. How to take Atazanavir
4. Possible side effects
5. How to store Atazanavir
6. Contents of the pack and other information
Atazanavir is an antiviral (or antiretroviral) medicine. It is one of a group called protease inhibitors. These medicines control Human Immunodeficiency Virus (HIV) infection by stopping a protein that the HIV needs for its multiplication. They work by reducing the amount of HIV in your body and this in turn, strengthens your immune system. In this way Atazanavir reduces the risk of developing illnesses linked to HIV infection.
Atazanavir capsules may be used by adults and children 6 years of age and older. Your doctor has prescribed Atazanavir for you because you are infected by the HIV that causes Acquired Immunodeficiency Syndrome (AIDS). It is normally used in combination with other anti-HIV medicines. Your doctor will discuss with you which combination of these medicines with Atazanavir is best for you.
Do not take sildenafil with Atazanavir when sildenafil is used for the treatment of pulmonary arterial hypertension. Sildenafil is also used for the treatment of erectile dysfunction. Tell your doctor if you are using sildenafil for the treatment of erectile dysfunction.
Tell your doctor at once if any of these apply to you.
Atazanavir is not a cure for HIV infection. You may continue to develop infections or other illnesses linked to HIV infection.
Some people will need special care before or while taking Atazanavir. Talk to your doctor or pharmacist before taking Atazanavir and make sure your doctor knows:
Atazanavir may affect how well your kidneys work.
Kidney stones have been reported in patients taking atazanavir. If you develop signs or symptoms of kidney stones (pain in your side, blood in your urine, pain when you urinate), please inform your doctor immediately.
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms. If you notice any symptoms of infection, please inform your doctor immediately. In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms please inform your doctor.
Hyperbilirubinaemia (an increase in the level of bilirubin in the blood) has occurred in patients receiving atazanavir. The signs may be a mild yellowing of the skin or eyes. If you notice any of these symptoms please inform your doctor.
Serious skin rash, including Stevens-Johnson syndrome, has been reported in patients taking atazanavir. If you develop a rash inform your doctor immediately.
If you notice a change in the way your heart beats (heart rhythm changes), please inform your doctor. Children receiving Atazanavir may require their heart to be monitored. Your child's doctor will decide this.
Do not give this medicine to children younger than 3 months of age and weighing less than 5 kg. The use of atazanavir in children less than 3 months of age and weighing less than 5 kg has not been studied due to the risk of serious complications.
You must not take Atazanavir with certain medicines. These are listed under Do not take Atazanavir, at the start of Section 2.
There are other medicines that may not mix with Atazanavir. Tell your doctor if you are taking, have recently taken, or might take any other medicines. It is especially important to mention these:
Some medicines may interact with ritonavir, a medicine that is taken with Atazanavir. It is important to tell your doctor if you are taking an inhaled or nasal (given in the nose) corticosteroid, including fluticasone or budesonide (given to treat allergic symptoms or asthma).
It is important that you take Atazanavir with food (a meal or a substantial snack) as this helps the body absorb the medicine.
If you are pregnant or think that you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Atazanavir, the active substance of Atazanavir, is excreted in human milk. Patients should not breastfeed while taking Atazanavir.
Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk
If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.
If you feel dizzy or lightheaded, do not drive or use machines and contact your doctor immediately.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. This way, you can be sure your medicine is fully effective and you reduce the risk of the virus developing resistance to the treatment.
The recommended adult dose of Atazanavir Capsules is 300 mg once daily with 100 mg ritonavir once daily and with food, in combination with other anti-HIV medicines. Your doctor may adjust the dose of Atazanavir according to your anti-HIV therapy.
For children (6 to less than 18 years of age), your child's doctor will decide the right dose based on your child's weight. The dose of Atazanavir Capsules for children is calculated by body weight and is taken once daily with food and 100 mg ritonavir as shown below:
Body Weight 15 to less than 35 kg:
Atazanavir Dose once daily is 200mg
Ritonavir Dose* once daily is 100mg
Body Weight at least 35 kg:
Atazanavir Dose once daily is 300mg
Ritonavir Dose* once daily is 100mg
*Ritonavir capsules, tablets or oral solution may be used.
Other forms of this medicine may be available for use in children at least 3 months old and weighing at least 5 kg. Switching to capsules from other formulations is encouraged as soon as patients are able to consistently swallow capsules.
A change in dose may occur when switching between other formulations and capsules. Your doctor will decide the right dose based on your child’s weight.
There are no dosing recommendations for Atazanavir in paediatric patients less than 3 months of age.
Take Atazanavir Capsules with food (a meal or a substantial snack). Swallow the capsules whole.
Do not open the capsules.
Yellowing of the skin and/or eyes (jaundice) and irregular heart beat (QTc prolongation) may occur if you or your child take too much Atazanavir.
If you accidentally take more Atazanavir capsules than your doctor recommended, contact your HIV doctor at once or contact the nearest hospital for advice.
If you miss a dose, take the missed dose as soon as possible with food and then take your next scheduled dose at its regular time. If it is almost time for your next dose, do not take the missed dose. Wait and take the next dose at its regular time. Do not take a double dose to make up for a forgotten dose.
Do not stop taking Atazanavir before talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them. When treating HIV infection, it is not always easy to identify what side effects are caused by Atazanavir, by the other medicines you are taking, or by the HIV infection itself. Tell your doctor if you notice anything unusual about your health.
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.
Tell your doctor immediately if you develop any of the following serious side effects:
Other side effects reported for patients treated with Atazanavir are the following:
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly via the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, bottle label or blister after EXP. The expiry date refers to the last day of that month.
Do not store above 30°C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is atazanavir.
Atazanavir 200 mg Capsules:
Each capsule contains 200 mg of atazanavir (as sulfate).
Atazanavir 300 mg Capsules:
Each capsule contains 300 mg of atazanavir (as sulfate).
The other ingredients are:
Atazanavir 200 mg hard capsules:
Lactose monohydrate, crospovidone (type A) (E1202), silica, colloidal anhydrous (E551), magnesium stearate (E470b).
The capsule shell and printing ink contain gelatin, titanium dioxide (E171), indigotine (E132), shellac, propylene glycol (E1520).
Atazanavir 300 mg hard capsules:
Lactose monohydrate, crospovidone (type A) (E1202), silica, colloidal anhydrous (E551), magnesium stearate (E470b). The capsule shell and printing ink contain gelatin, titanium dioxide (E171), indigotine (E132), red iron oxide (E172), shellac, propylene glycol (E1520).
Atazanavir 200 mg hard capsules:
Opaque, blue capsule of size 0 printed with white ink, with “200 mg” on the cap.
Atazanavir 300 mg hard capsules:
Opaque red and blue capsule of size 00 printed with white ink, with “300 mg” on the cap.
Atazanavir 200 mg hard capsules:
Atazanavir is supplied in Aluminium-OPA/Alu/PVC blisters containing 60 hard capsules.
Atazanavir is supplied in Aluminium-OPA/Alu/PVC unit dose perforated blisters containing 60 x 1 hard capsules.
Atazanavir 300 mg hard capsules:
Atazanavir is supplied in Aluminium-OPA/Alu/PVC blisters containing 12 hard capsules.
Atazanavir is supplied in Aluminium-OPA/Alu/PVC blisters containing 30 hard capsules.
Atazanavir is supplied in Aluminium-OPA/Alu/PVC unit dose perforated blisters containing 30 x 1 hard capsules
Atazanavir is supplied in multipack containing 60 (2 packs of 30) hard capsules in Aluminium-OPA/Alu/PVC blisters.
Atazanavir is supplied in multipack containing 90 (3 packs of 30) hard capsules in AluminiumOPA/Alu/PVC blisters.
Atazanavir is supplied in multipack containing 90 x 1 (3 packs of 30 x 1) hard capsules in Aluminium-OPA/Alu/PVC unit dose perforated blisters.
Not all pack sizes may be marketed.
This leaflet was last revised in 07/2024
Dr. Reddy's Laboratories (UK) Limited, 410 Cambridge Science Park, Milton Road, Cambridge, CB4 0PE, UK
+44 (0)1748 828 873
+44 (0)1223 651 475
+44 (0)1223 728 010
http://www.drreddys.com/united-kingdom